The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- Valuing and accessing medicines
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- Health Data
Valuing and accessing medicines
Ensuring value, access and uptake of innovative medicines and vaccines, now and in the future
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
Improving the UK's attractiveness for industry, research, development and manufacturing
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
Building better partnerships between industry and NHS and across the Life Sciences sector
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
Building a stronger industry reputation in the UK
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
Providing international leadership and driving global policy
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
Health Data
Improving the UK's health data capability and industry's access to data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
Rescuing patient access to industry clinical trials in the UK
The ABPI's latest report shows a collapse in the number of UK industry clinical trials.
Read the report
Comparing Outcomes
Pre-and Post-Cancer
Drugs Fund
Now that a number of medicines have exited the Cancer Drugs Fund (CDF), the ABPI commissioned Lumanity to explore how it has been operating, including how well clinical outcomes are being predicted by manufacturers at the time of entry to the fund on initial appraisal. The findings are published in this report ‘Comparing Outcomes Pre- and Post-Cancer Drugs Fund: What Can We Learn?’
Read the report and our blogLatest news
ABPI response to MHRA future Medical Device Regulation implementation extension
The extension will mean industry will have until July 2024 to ensure their medical devices meet the new regulations.
NHS patients losing access to innovative treatments as UK industry clinical trials face collapse
The ABPI's latest report shows a collapse in the number of UK industry clinical trials.
ABPI response to NHS England Genomics Strategy
NHS England has today published its first Genomics Strategy.
New survey shows collaboration between pharmaceutical industry and UK academia is growing
The ABPI has published its latest survey on the links between industry and academia.
Latest blogs and events
Reflections from NICON22
Commentary on this year's Northern Ireland Annual Conference and Exhibition 2022.
Could more medicines be recommended for routine commissioning rather than spending time in the Cancer Drugs Fund?
A new analysis commissioned by the ABPI suggests they could.
The Innovative Medicines Fund - Good news for patients but has an opportunity been missed to be more ambitious?
NHS England and Improvement (NHSE/I) has announced the launch of the Innovative Medicines Fund. The ABPI’s Director of Value and Access Policy, Paul Catchpole, provides further commentary on the announcement.
Working together, we are all determined to create more medicines for pregnant women
Steve Hoare, the ABPI's Head of Safety and Quality, talks about how industry is trying to address the lack of medicines approved for pregnant women.
Key content hubs
This covers the latest research from the ABPI-Ipsos attitudes towards pharmaceutical companies in the UK study.
We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
Great to join a panel with Nick Meade of @GeneticAll_UK, Owen Marks of @Pfizer_UK & Kate Irving of @TakedaPharma at the @ABPI_UK Rare Disease Forum and hear of progress on the Rare Disease Framework and Action Plans. Clearly some good collaborative opportunities for rare cancers!
— Cancer52 💙 #DoYouCUs (@Cancer52org) November 2, 2022
Looking forward to speaking at next week’s FT Pharma & Biotech conference. Do get in touch if you happen to be there https://t.co/Abr6QwXAqd
— Richard Torbett (@TorbettR) November 1, 2022
A report by @ABPI_UK has shed light on the current climate of UK industry clinical trials. It shows that in 2021/22, the number of industry clinical trials initiated in the UK fall by 41% between 2017 and 2021.
— Brain Tumour Research (@braintumourrsch) November 1, 2022
Read more ➡️ https://t.co/tFmohAt8dG pic.twitter.com/XciMv2dSOY
We are pleased to be partnering with @HDR_UK on their scientific conference - join us on 14 December 🔽 https://t.co/kXxcyiKCyu
— ABPI (@ABPI_UK) November 1, 2022
The Pharmaceutical Industry in the UK
![R and D Investment [3]](/media/ouqnhlry/figures-r-d-investment-5-0bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.